Chapter 80
Diabetes Mellitus Related to Diseases of the Exocrine Pancreas (Pancreatogenic Diabetes)
Diagnosis and Treatment
David A. Bradley,
Phil A. Hart,
David A. Bradley
Diabetes & Metabolism Research Center, Division of Endocrinology, Diabetes & Metabolism, The Ohio State University Wexner Medical Center, Columbus, OH, USA
Search for more papers by this authorPhil A. Hart
Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA
Search for more papers by this authorDavid A. Bradley,
Phil A. Hart,
David A. Bradley
Diabetes & Metabolism Research Center, Division of Endocrinology, Diabetes & Metabolism, The Ohio State University Wexner Medical Center, Columbus, OH, USA
Search for more papers by this authorPhil A. Hart
Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA
Search for more papers by this authorBook Editor(s):J. Enrique Domínguez-Muñoz MD, PhD,
J. Enrique Domínguez-Muñoz MD, PhD
Director
Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
Search for more papers by this authorFirst published: 16 April 2021
Summary
Pancreatogenic diabetes mellitus (type 3c DM) refers to DM that develops secondary to diseases of the exocrine pancreas. This chapter describes the epidemiology and approach to diagnosis and treatment of pancreatogenic DM. Additionally, the accurate diagnosis of pancreatogenic DM caused by pancreatic cancer, i.e. pancreatic ductal adenocarcinoma (PDAC), is particularly critical as early diagnosis may provide an opportunity for early cancer detection. The prevalence and pathophysiology of pancreatogenic DM differs based on the underlying pancreatic disease. Diabetes mellitus occurs in the setting of a dysregulated metabolic state that eventually culminates in chronic systemic hyperglycemia. The primary deficiency in CP-DM is inadequate insulin secretion, so therapeutic decisions should be guided by this underlying pathophysiology.
References
- Hart PA, Bellin MD, Andersen DK, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol 2016; 1: 226–237.
- Ewald N, Kaufmann C, Raspe A, et al. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev 2012; 28: 338–342.
- Hardt PD, Brendel MD, Kloer HU, et al. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? Diabetes Care 2008; 31(Suppl 2): S165–S169.
- Woodmansey C, McGovern AP, McCullough KA, et al. Incidence, demographics, and clinical characteristics of diabetes of the exocrine pancreas (type 3c): a retrospective cohort study. Diabetes Care 2017; 40: 1486–1493.
- Hart PA, Kamada P, Rabe KG, et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas 2011; 40: 768–772.
- Bellin MD, Whitcomb DC, Abberbock J, et al. Patient and disease characteristics associated with the presence of diabetes mellitus in adults with chronic pancreatitis in the United States. Am J Gastroenterol 2017; 112: 1457–1465.
- Wang W, Guo Y, Liao Z, et al. Occurrence of and risk factors for diabetes mellitus in Chinese patients with chronic pancreatitis. Pancreas 2011; 40: 206–212.
- Kumar K, Sharma R, Manrai M, et al. Visceral adipose tissue as a risk factor for diabetes mellitus in patients with chronic pancreatitis: a cross-sectional, observational study. Diabetes Ther 2017; 8: 1057–1064.
- Lundberg R, Beilman GJ, Dunn TB, et al. Early alterations in glycemic control and pancreatic endocrine function in nondiabetic patients with chronic pancreatitis. Pancreas 2016; 45: 565–571.
- Brunicardi FC, Chaiken RL, Ryan AS, et al. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 1996; 81: 3566–3572.
- Kwon JH, Kim SC, Shim IK, et al. Factors affecting the development of diabetes mellitus after pancreatic resection. Pancreas 2015; 44: 1296–1303.
- Scholten L, Mungroop TH, Haijtink SAL, et al. New-onset diabetes after pancreatoduodenectomy: a systematic review and meta-analysis. Surgery 2018; 164(1): 6–16.
- Burkhart RA, Gerber SM, Tholey RM, et al. Incidence and severity of pancreatogenic diabetes after pancreatic resection. J Gastrointest Surg 2015; 19: 217–225.
- Kang JS, Jang JY, Kang MJ, et al. Endocrine function impairment after distal pancreatectomy: incidence and related factors. World J Surg 2016; 40: 440–446.
- Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology 2000; 119: 1324–1332.
- De Bruijn KM, van Eijck CH. New-onset diabetes after distal pancreatectomy: a systematic review. Ann Surg 2015; 261: 854–861.
- Chinnakotla S, Beilman GJ, Dunn TB, et al. Factors predicting outcomes after a total pancreatectomy and islet autotransplantation: lessons learned from over 500 cases. Ann Surg 2015; 262: 610–622.
- Das SL, Singh PP, Phillips AR, et al. Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Gut 2014; 63: 818–831.
- Tu J, Yang Y, Zhang J, et al. Effect of the disease severity on the risk of developing new-onset diabetes after acute pancreatitis. Medicine (Baltimore) 2018; 97: e10713.
- Vipperla K, Papachristou GI, Slivka A, et al. Risk of new-onset diabetes is determined by severity of acute pancreatitis. Pancreas 2016; 45: e14–e15.
- Pendharkar SA, Singh RG, Bharmal SH, et al. Pancreatic hormone responses to mixed meal test in new-onset prediabetes/diabetes after non-necrotizing acute pancreatitis. J Clin Gastroenterol 2020; 54(2): e11–e20.
- Moran A, Pillay K, Becker D, et al. ISPAD Clinical Practice Consensus Guidelines 2018: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2018; 19(Suppl 27): 64–74.
- Moran A, Dunitz J, Nathan B, et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009; 32: 1626–1631.
- Rickels MR, Bellin M, Toledo FG, et al. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology 2013; 13: 336–342.
- Hart PA, Andersen DK, Mather KJ, et al. Evaluation of a mixed meal test for diagnosis and characterization of pancreatogenic diabetes secondary to pancreatic cancer and chronic pancreatitis: rationale and methodology for the DETECT Study from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 2018; 47: 1239–1243.
- Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol 2013; 19: 7276–7281.
- Leeds JS, Oppong K, Sanders DS. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol 2011; 8: 405–415.
- Gutch M, Kumar S, Razi SM, et al. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab 2015; 19: 160–164.
- Deng T, Liu J, Deng Y, et al. Adipocyte adaptive immunity mediates diet-induced adipose inflammation and insulin resistance by decreasing adipose Treg cells. Nat Commun 2017; 8: 15725.
- Agarwal S, Yadav A, Chaturvedi RK. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders. Biochem Biophys Res Commun 2017; 483: 1166–1177.
- Shayo M, McLay RN, Kastin AJ, et al. The putative blood–brain barrier transporter for the beta-amyloid binding protein apolipoprotein j is saturated at physiological concentrations. Life Sci 1997; 60: PL115–118.
- Tiengo A, Segato T, Briani G, et al. The presence of retinopathy in patients with secondary diabetes following pancreatectomy or chronic pancreatitis. Diabetes Care 1983; 6: 570–574.
- Ziegler O, Candiloros H, Guerci B, et al. Lower-extremity arterial disease in diabetes mellitus due to chronic pancreatitis. Diabete Metab 1994; 20: 540–545.
- Liao KF, Lai SW, Li CI, et al. Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol 2012; 27: 709–713.
- Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer 2012; 19: F9–F26.
- Beffert U, Nematollah Farsian F, Masiulis I, et al. ApoE receptor 2 controls neuronal survival in the adult brain. Curr Biol 2006; 16: 2446–2452.
- Rebours V, Boutron-Ruault MC, Schnee M, et al. The natural history of hereditary pancreatitis: a national series. Gut 2009; 58: 97–103.
- Ahren B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013; 9: 155–163.
- Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012; 17: 813–822.
- Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150–156.
- Takahashi K, Nakamura A, Miyoshi H, et al. Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. Sci Rep 2018; 8: 6864.
- Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017; 376: 2300–2302.
- Gonzalez-Perez A, Schlienger RG, Rodriguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 2010; 33: 2580–2585.
- Blomgren KB, Sundstrom A, Steineck G, et al. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002; 25: 298–302.
- Giorda CB, Sacerdote C, Nada E, et al. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine 2015; 48: 461–471.
- Wang T, Wang F, Gou Z, et al. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Diabetes Obes Metab 2015; 17: 32–41.
- Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482–488.
- Wang Z, Lai ST, Xie L, et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 2014; 106: 19–26.
- Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 510–519; quiz 520.
- Dong YW, Shi YQ, He LW, et al. Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis. Oncotarget 2017; 8: 55478–55488.
- Reni M, Dugnani E, Cereda S, et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial. Clin Cancer Res 2016; 22: 1076–1085.
- Kordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2015; 16: 839–847.
- Andersen DK, Andren-Sandberg A, Duell EJ, et al. Pancreatitis–diabetes–pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 2013; 42: 1227–1237.
- Gardner TB, Hessami N, Smith KD, et al. The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus. Pancreas 2014; 43: 1018–1021.
- Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134: 981–987.
- Marshall BC, Butler SM, Stoddard M, et al. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005; 146: 681–687.
- Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000; 162: 891–895.
- Moran A, Pekow P, Grover P, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the Cystic Fibrosis Related Diabetes Therapy Trial. Diabetes Care 2009; 32: 1783–1788.
- Brennan AL, Gyi KM, Wood DM, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 2007; 6: 101–109.
- Hunt WR, Zughaier SM, Guentert DE, et al. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol 2014; 306: L43–L49.
- Bilodeau C, Bardou O, Maille E, et al. Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair. J Cyst Fibros 2016; 15: 43–51.
- Lanng S, Thorsteinsson B, Pociot F, et al. Diabetes mellitus in cystic fibrosis: genetic and immunological markers. Acta Paediatr 1993; 82: 150–154.
- Konrad K, Kapellen T, Lilienthal E, et al. Does beta-cell autoimmunity play a role in cystic fibrosis-related diabetes? Analysis based on the German/Austrian Diabetes Patienten Verlaufsdokumentation Registry. Diabetes Care 2016; 39: 1338–1344.
- Blackman SM, Hsu S, Ritter SE, et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009; 52: 1858–1865.
- Lanng S, Thorsteinsson B, Lund-Andersen C, et al. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr 1994; 83: 72–77.
- van den Berg JM, Morton AM, Kok SW, et al. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008; 7: 515–519.
- Rosenecker J, Hofler R, Steinkamp G, et al. Diabetes mellitus in patients with cystic fibrosis: the impact of diabetes mellitus on pulmonary function and clinical outcome. Eur J Med Res 2001; 6: 345–350.
- Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33: 2697–2708.
- Milner AD. Blood glucose and serum insulin levels in children with cystic fibrosis. Arch Dis Child 1969; 44: 351–355.
- Wilmshurst EG, Soeldner JS, Holsclaw DS, et al. Endogenous and exogenous insulin responses in patients with cystic fibrosis. Pediatrics 1975; 55: 75–82.
- Sheikh S, Gudipaty L, De Leon DD, et al. Reduced beta-cell secretory capacity in pancreatic-insufficient, but not pancreatic-sufficient, cystic fibrosis despite normal glucose tolerance. Diabetes 2017; 66: 134–144.
- Moran A, Becker D, Casella SJ, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010; 33: 2677–2683.
- Mohan K, Israel KL, Miller H, et al. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration 2008; 76: 181–186.
- Lanng S, Thorsteinsson B, Nerup J, et al. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994; 83: 849–853.
- Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr 2001; 90: 515–519.
- Dobson L, Hattersley AT, Tiley S, et al. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child 2002; 87: 430–431.
- Franzese A, Spagnuolo MI, Sepe A, et al. Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes? Diabetes Care 2005; 28: 2333.
- Mozzillo E, Franzese A, Valerio G, et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes 2009; 10: 162–167.
- Hameed S, Morton JR, Field PI, et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch Dis Child 2012; 97: 464–467.
- Sunni M, Bellin MD, Moran A. Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes. Pediatr Diabetes 2013; 14: 295–298.
- Balzer BW, Graham CL, Craig ME, et al. Low glycaemic index dietary interventions in youth with cystic fibrosis: a systematic review and discussion of the clinical implications. Nutrients 2012; 4: 286–296.
- Ollero M, Junaidi O, Zaman MM, et al. Decreased expression of peroxisome proliferator activated receptor gamma in cftr–/– mice. J Cell Physiol 2004; 200: 235–244.
- Konstan MW GD, Hilliard K, Hilliard J. A pilot study evaluating the effect of pioglitazone, simvastatin, and ibuprofen on neutrophil migration in vivo in healthy subjects. Pediatr Pulmonol 2009; 44: 230–238.
- Riche DM, King ST. Bone loss and fracture risk associated with thiazolidinedione therapy. Pharmacotherapy 2010; 30: 716–727.
- Stalvey MS, Clines GA. Cystic fibrosis-related bone disease: insights into a growing problem. Curr Opin Endocrinol Diabetes Obes 2013; 20: 547–552.
- Hillman M, Eriksson L, Mared L, et al. Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros 2012; 11: 144–149.
- Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173: 534–539.
- Astrand A, Wingren C, Benjamin A, et al. Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice. Br J Pharmacol 2017; 174: 836–847.
